<DOC>
	<DOCNO>NCT00047736</DOCNO>
	<brief_summary>The purpose study determine Tarceva plus standard chemotherapy effective standard chemotherapy alone treatment lung cancer .</brief_summary>
	<brief_title>A Study With Tarceva Chemotherapy v . Chemotherapy Alone Patients With Advanced Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Signed informed consent Age &gt; =18 year Histologically document , unresectable , inoperable , locally advanced , recurrent metastatic Stage IIIB Stage IV NonSmall Cell Lung Cancer ( NSCLC ) A cytologic diagnosis acceptable ( i.e. , FNA pleural fluid cytology ) Measurable nonmeasurable disease ECOG performance status 0 1 Life expectancy &gt; =3 month &gt; = 3 week since prior surgery radiotherapy ( &gt; =2 week patient receive &lt; =30 Gy radiotherapy involve &lt; 25 % marrow reserve ) Use effective mean contraception ( woman childbearing potential ) Able comply study followup procedure Evidence small cell , carcinoid , mixed small cell/nonsmall cell histology Malignancies within 3 year except adequately treat carcinoma situ cervix basal squamous cell skin cancer Symptomatic untreated brain metastasis Prior systemic chemotherapy NSCLC Prior exposure agent direct HER axis ( e.g. , ZD1839 [ Iressa ] , C225 [ Cetuximab ] , Trastuzumab [ Herceptin ] ) Unstable systemic disease , include active infection , uncontrolled hypertension , unstable angina , congestive heart failure , myocardial infarction within 6 month prior Day 1 , serious cardiac arrhythmia require medication ( patient chronic atrial arrhythmia , i.e. , atrial fibrillation paroxysmal supraventricular tachycardia , eligible ) History disease , metabolic dysfunction , physical examination finding , clinical laboratory find give reasonable suspicion disease condition contraindicate use investigational drug might affect interpretation result study render patient high risk treatment complication Gastrointestinal tract disease result inability take oral medication requirement intravenous ( IV ) alimentation , prior surgical procedure affect absorption Pregnancy lactation Any follow abnormal baseline hematologic value : Granulocytes count &lt; =1500/uL Platelet count &lt; 100,000/uL Any follow abnormal baseline liver function test : Serum bilirubin &gt; 1.5× upper limit normal ( ULN ) Serum ALT AST &gt; =2.5× ULN ( &gt; 5× ULN due liver metastasis ) Alkaline phosphatase &gt; =2.5× ULN Other baseline laboratory value : Serum creatinine &gt; 1.5× ULN creatinine clearance &lt; 60 mL/min Uncontrolled hypercalcemia ( &gt; 11.5 mg/dL )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
	<keyword>Non-small cell lung cancer</keyword>
</DOC>